Roberta B. Ness
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roberta B. Ness has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
David E. Soper
3 shared publicationsDeborah B. Nelson
3 shared publicationsDebra C. Bass
3 shared publicationsHolly E. Richter
3 shared publicationsJeffrey F. Peipert
3 shared publicationsWayne Trout
3 shared publications
Latest Publications
- 1 June 2008
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 198 (6) , 620.e1-620.e4
Male reproductive proteins and reproductive outcomes
- 1 June 2008
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 198 (6) , 620.e1-620.e4
Male reproductive proteins and reproductive outcomes
- 1 February 2008
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 35 (2) , 129-135
Chlamydia Antibodies, Chlamydia Heat Shock Protein, and Adverse Sequelae After Pelvic Inflammatory Disease: The PID Evaluation and Clinical Health (PEACH) Study
Among women with pelvic inflammatory disease (PID), we assessed the associations among antibodies to Chlamydia trachomatis elementary bodies (EB), antibodies to chlamydia heat shock protein (Chsp60), rates of pregnancy, and PID recurrence. Four hundred forty-three women with clinical signs and symptoms of mild to moderate PID enrolled in the PID Evaluation and Clinical Health Study were followed for a mean of 84 months for outcomes of time-to-pregnancy and time-to-PID recurrence. Antibodies to EB and Chsp60 were assessed in relation to these long-term sequelae of PID. Rates of pregnancy were significantly lower (adj. hazard ratio 0.47, 95% confidence interval 0.28–0.79) and PID recurrence higher (adj. hazard ratio 2.48, 95% confidence interval 1.00–6.27) after adjusting for confounding factors among women whose antibody titers to chlamydia EB measured in the final year of follow-up were in the highest tertile. Among women with mild to moderate PID, antibodies to C. trachomatis were independently associated with reduced rates of pregnancy and elevated rates of recurrent PID.
- 1 February 2008
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 35 (2) , 129-135
Chlamydia Antibodies, Chlamydia Heat Shock Protein, and Adverse Sequelae After Pelvic Inflammatory Disease: The PID Evaluation and Clinical Health (PEACH) Study
Among women with pelvic inflammatory disease (PID), we assessed the associations among antibodies to Chlamydia trachomatis elementary bodies (EB), antibodies to chlamydia heat shock protein (Chsp60), rates of pregnancy, and PID recurrence. Four hundred forty-three women with clinical signs and symptoms of mild to moderate PID enrolled in the PID Evaluation and Clinical Health Study were followed for a mean of 84 months for outcomes of time-to-pregnancy and time-to-PID recurrence. Antibodies to EB and Chsp60 were assessed in relation to these long-term sequelae of PID. Rates of pregnancy were significantly lower (adj. hazard ratio 0.47, 95% confidence interval 0.28–0.79) and PID recurrence higher (adj. hazard ratio 2.48, 95% confidence interval 1.00–6.27) after adjusting for confounding factors among women whose antibody titers to chlamydia EB measured in the final year of follow-up were in the highest tertile. Among women with mild to moderate PID, antibodies to C. trachomatis were independently associated with reduced rates of pregnancy and elevated rates of recurrent PID.
- 1 January 2008
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 198 (1) , 30.e1-30.e7
Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?
- 1 January 2008
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 198 (1) , 30.e1-30.e7
Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?
- 14 November 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 298 (18) , 2164-2170
Influence of the HIPAA Privacy Rule on Health Research
Research from JAMA — Influence of the HIPAA Privacy Rule on Health Research — ContextAnecdotal reports suggest that the Health Insurance Portability and Accountability Act Privacy Rule (HIPAA Privacy Rule) may be affecting health research in the United States.ObjectiveTo survey epidemiologists about their experiences with the HIPAA Privacy Rule.Design, Setting, and ParticipantsThirteen societies of epidemiology distributed a national Web-based survey; 2805 respondents accessed the survey Web site and 1527 eligible professionals anonymously answered questions.Main Outcome MeasuresResponses related influences such as research delays and added cost after Privacy Rule implementation, frequency and type of Privacy Rule–related institutional review board modifications, level of difficulty obtaining deidentified data and waivers, experiences with multisite studies, and perceived participant privacy benefits under the rule. Respondents ranked their perceptions of Privacy Rule influence on 5-point Likert scales.ResultsA total of 875 (67.8%) respondents reported that the HIPAA Privacy Rule has made research more difficult at a level of 4 to 5 on a Likert scale, in which 5 indicates a great deal of added cost and time to study completion. A total of 684 (52.1%) of respondents identified a “most affected” protocol. Respondents indicated that the proportion of institutional review board applications in which the Privacy Rule had a negative influence on human subjects (participants) protection was significantly greater than the proportion in which it had a positive influence (P < .001).ConclusionIn this national survey of clinical scientists, only a quarter perceived that the rule has enhanced participants' confidentiality and privacy, whereas the HIPAA Privacy Rule was perceived to have a substantial, negative influence on the conduct of human subjects health research, often adding uncertainty, cost, and delay.
- 14 November 2007
- Published by American Medical Association (AMA) in JAMA
- Vol. 298 (18) , 2164-2170
Influence of the HIPAA Privacy Rule on Health Research
Research from JAMA — Influence of the HIPAA Privacy Rule on Health Research — ContextAnecdotal reports suggest that the Health Insurance Portability and Accountability Act Privacy Rule (HIPAA Privacy Rule) may be affecting health research in the United States.ObjectiveTo survey epidemiologists about their experiences with the HIPAA Privacy Rule.Design, Setting, and ParticipantsThirteen societies of epidemiology distributed a national Web-based survey; 2805 respondents accessed the survey Web site and 1527 eligible professionals anonymously answered questions.Main Outcome MeasuresResponses related influences such as research delays and added cost after Privacy Rule implementation, frequency and type of Privacy Rule–related institutional review board modifications, level of difficulty obtaining deidentified data and waivers, experiences with multisite studies, and perceived participant privacy benefits under the rule. Respondents ranked their perceptions of Privacy Rule influence on 5-point Likert scales.ResultsA total of 875 (67.8%) respondents reported that the HIPAA Privacy Rule has made research more difficult at a level of 4 to 5 on a Likert scale, in which 5 indicates a great deal of added cost and time to study completion. A total of 684 (52.1%) of respondents identified a “most affected” protocol. Respondents indicated that the proportion of institutional review board applications in which the Privacy Rule had a negative influence on human subjects (participants) protection was significantly greater than the proportion in which it had a positive influence (P < .001).ConclusionIn this national survey of clinical scientists, only a quarter perceived that the rule has enhanced participants' confidentiality and privacy, whereas the HIPAA Privacy Rule was perceived to have a substantial, negative influence on the conduct of human subjects health research, often adding uncertainty, cost, and delay.
- Open Access
- 1 September 2005
- Published by SAGE Publications in Women's Health
- Vol. 1 (2) , 245-251
Intersections between Adverse Pregnancy Outcomes
Reproductive failure in a variety of forms, whether it be infertility, miscarriage, pre-eclampsia, prematurity or intrauterine growth restriction, may aggregate within individuals. This observation, although rarely studied, suggests that single pathophysiologies may be associated with a variety of reproductive morbidities. In this review, hyperimmune responsiveness to pregnancy is provided as one example of a process leading to a multitude of adverse impacts on healthy childbearing. Further research on reproductive failure as a spectrum is warranted.
- 1 September 2005
- Published by SAGE Publications in Women's Health
- Vol. 1 (2) , 245-251
Open AccessIntersections between Adverse Pregnancy Outcomes
Reproductive failure in a variety of forms, whether it be infertility, miscarriage, pre-eclampsia, prematurity or intrauterine growth restriction, may aggregate within individuals. This observation, although rarely studied, suggests that single pathophysiologies may be associated with a variety of reproductive morbidities. In this review, hyperimmune responsiveness to pregnancy is provided as one example of a process leading to a multitude of adverse impacts on healthy childbearing. Further research on reproductive failure as a spectrum is warranted.
- 1 September 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 106 (3) , 573-580
Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease
Among all women with pelvic inflammatory disease (PID), prevention of adverse reproductive consequences appears to be similarly achieved by outpatient treatment and inpatient treatment. We assessed whether outpatient is as effective as inpatient treatment in relevant age, race, and clinical subgroups of women with PID. Women with clinical signs and symptoms of mild-to-moderate pelvic inflammatory disease (n = 831) were randomized into a multicenter trial of inpatient treatment, initially employing intravenous cefoxitin and doxycycline compared with outpatient treatment consisting of a single intramuscular injection of cefoxitin and oral doxycycline. Comparisons between treatment groups during a mean of 84 months of follow-up were made for pregnancies, live births, time to pregnancy, infertility, PID recurrence, chronic pelvic pain, and ectopic pregnancy. Outpatient treatment assignment did not adversely impact the proportion of women having one or more pregnancies, live births, or ectopic pregnancies during follow-up; time to pregnancy; infertility; PID recurrence; or chronic pelvic pain among women of various races; with or without previous PID; with or without baseline Neisseria gonorrhoeae and/or Chlamydia trachomatis infection; and with or without high temperature/white blood cell count/pelvic tenderness score. This was true even in teenagers and women without a previous live birth. Ectopic pregnancies were more common in the outpatient than the inpatient treatment group, but because these were so rare, the difference did not reach statistical significance (5 versus 1, odds ratio 4.91, 95% confidence interval 0.57-42.25). Among all women and subgroups of women with mild-to-moderate PID, there were no differences in reproductive outcomes after randomization to inpatient or outpatient treatment. I.
- 1 September 2005
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 106 (3) , 573-580
Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease
Among all women with pelvic inflammatory disease (PID), prevention of adverse reproductive consequences appears to be similarly achieved by outpatient treatment and inpatient treatment. We assessed whether outpatient is as effective as inpatient treatment in relevant age, race, and clinical subgroups of women with PID. Women with clinical signs and symptoms of mild-to-moderate pelvic inflammatory disease (n = 831) were randomized into a multicenter trial of inpatient treatment, initially employing intravenous cefoxitin and doxycycline compared with outpatient treatment consisting of a single intramuscular injection of cefoxitin and oral doxycycline. Comparisons between treatment groups during a mean of 84 months of follow-up were made for pregnancies, live births, time to pregnancy, infertility, PID recurrence, chronic pelvic pain, and ectopic pregnancy. Outpatient treatment assignment did not adversely impact the proportion of women having one or more pregnancies, live births, or ectopic pregnancies during follow-up; time to pregnancy; infertility; PID recurrence; or chronic pelvic pain among women of various races; with or without previous PID; with or without baseline Neisseria gonorrhoeae and/or Chlamydia trachomatis infection; and with or without high temperature/white blood cell count/pelvic tenderness score. This was true even in teenagers and women without a previous live birth. Ectopic pregnancies were more common in the outpatient than the inpatient treatment group, but because these were so rare, the difference did not reach statistical significance (5 versus 1, odds ratio 4.91, 95% confidence interval 0.57-42.25). Among all women and subgroups of women with mild-to-moderate PID, there were no differences in reproductive outcomes after randomization to inpatient or outpatient treatment. I.
- Open Access
- 1 December 2004
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 160 (11) , 1033-1038
Differential Distribution of Allelic Variants in Cytokine Genes among African Americans and White Americans
Racial disparities in health are largely unexplained. Because many diseases causing premature mortality among African Americans are mediated by the immune system, the authors explored the race-specific distribution of allelic variants in cytokine genes known to stimulate inflammation. The authors studied women seeking prenatal care and delivering singletons in uncomplicated first births at a US hospital in 1997–2001. A total of 179 African-American women and 396 White women were evaluated for functionally relevant allelic variants in cytokine genes. African-American women were significantly more likely to carry allelic variants known to up-regulate proinflammatory cytokines; odds ratios increased with allele dose. Odds ratios for African Americans versus Whites in genotypes up-regulating proinflammatory interleukin (IL) 1 (IL1A-4845G/G, IL1A-889T/T, IL1B-3957C/C, and IL1B-511A/A) ranged from 2.1 to 4.9. The proinflammatory cytokine interleukin-6 IL6-174 G/G genotype was 36.5 times (95% confidence interval (CI): 8.8, 151.9) more common among African Americans. Genotypes known to down-regulate the antiinflammatory interleukin-10 (IL10-819 T/T and IL10-1082 A/A) were elevated 3.5-fold (95% CI: 1.8, 6.6) and 2.8-fold (95% CI: 1.6, 4.9) in African Americans. Cytokine genotypes found to be more common in African-American women were consistently those that up-regulate inflammation.
- 1 December 2004
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 160 (11) , 1033-1038
Open AccessDifferential Distribution of Allelic Variants in Cytokine Genes among African Americans and White Americans
Racial disparities in health are largely unexplained. Because many diseases causing premature mortality among African Americans are mediated by the immune system, the authors explored the race-specific distribution of allelic variants in cytokine genes known to stimulate inflammation. The authors studied women seeking prenatal care and delivering singletons in uncomplicated first births at a US hospital in 1997–2001. A total of 179 African-American women and 396 White women were evaluated for functionally relevant allelic variants in cytokine genes. African-American women were significantly more likely to carry allelic variants known to up-regulate proinflammatory cytokines; odds ratios increased with allele dose. Odds ratios for African Americans versus Whites in genotypes up-regulating proinflammatory interleukin (IL) 1 (IL1A-4845G/G, IL1A-889T/T, IL1B-3957C/C, and IL1B-511A/A) ranged from 2.1 to 4.9. The proinflammatory cytokine interleukin-6 IL6-174 G/G genotype was 36.5 times (95% confidence interval (CI): 8.8, 151.9) more common among African Americans. Genotypes known to down-regulate the antiinflammatory interleukin-10 (IL10-819 T/T and IL10-1082 A/A) were elevated 3.5-fold (95% CI: 1.8, 6.6) and 2.8-fold (95% CI: 1.6, 4.9) in African Americans. Cytokine genotypes found to be more common in African-American women were consistently those that up-regulate inflammation.